Sangamo Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Gena Wang. I'm SMID Cap Biotech Analyst. It's my great pleasure to introduce our first speaker Stéphane Boissel, EVP of the Corporate Strategy, to give a presentation; and also with us is McDavid Stilwell, Head of IR and Communication.
© -
Thank you, Gena. Well, good morning. My name is Stéphane Boissel. I'm Head of Corporate Strategy at Sangamo. Prior to that, I was the CEO of TxCell, which was sold to Sangamo in the fall.
Before I go through the presentation, I encourage you to read the forward-looking statements. And assuming you've done so, let's move into the presentation, and I will start with a very simple slide. So we like to define ourselves at Sangamo as a genomic medicine company. And when we say that, we are often asked, so what does that mean? That means that we use genomic information from the patient to develop therapies, and we are quite
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
